Stock Options and Warrants |
8. |
Stock Options and Warrants |
The Company periodically issues
stock options and warrants to employees and non-employees in capital raising transactions, for services and for financing costs. Options
and warrants vest and expire according to terms established at the grant date.
Options
Employee options vest according
to the terms of the specific grant and expire from 5 to 10 years from date of grant. The weighted average, remaining contractual life
of employee and non-employee options outstanding at December 31, 2020 was 5.5 years. Stock option activity for the period January 1, 2019
to December 31, 2020, was as follows:
|
|
Options |
|
|
Weighted Avg. Exercise Price
|
|
Options outstanding, December 31, 2018 |
|
|
35,301,300 |
|
|
$ |
0.22 |
|
Options granted |
|
|
4,987,500 |
|
|
|
0.08 |
|
Options exercised |
|
|
(538,197 |
) |
|
|
0.13 |
|
Options cancelled |
|
|
– |
|
|
|
– |
|
Options outstanding, December 31, 2019 |
|
|
39,750,603 |
|
|
$ |
0.20 |
|
Options granted |
|
|
3,599,998 |
|
|
|
0.12 |
|
Options exercised |
|
|
(60,000 |
) |
|
|
0.05 |
|
Options cancelled |
|
|
(10,810,000 |
) |
|
|
0.25 |
|
Options outstanding, December 31, 2020 |
|
|
32,480,601 |
|
|
$ |
0.18 |
|
The weighted average exercise
prices, remaining contractual lives for options granted, exercisable, and expected to vest as of December 31, 2020 were as follows:
|
|
Outstanding Options |
|
|
Exercisable Options |
|
Option
Exercise Price
Per Share
|
|
Shares |
|
|
Life
(Years) |
|
|
Weighted Average Exercise Price |
|
|
Shares |
|
|
Weighted Average Exercise Price |
|
$ 0.05 - $ 0.24 |
|
|
21,505,551 |
|
|
|
7.0 |
|
|
$ |
0.10 |
|
|
|
21,405,551 |
|
|
$ |
0.10 |
|
$ 0.25 - $ 0.49 |
|
|
10,353,552 |
|
|
|
2.5 |
|
|
|
0.30 |
|
|
|
10,353,552 |
|
|
|
0.30 |
|
$ 0.50 - $ 0.99 |
|
|
471,052 |
|
|
|
3.3 |
|
|
|
0.85 |
|
|
|
471,052 |
|
|
|
0.85 |
|
$ 1.00 - $ 2.00 |
|
|
150,446 |
|
|
|
2.6 |
|
|
|
1.18 |
|
|
|
150,446 |
|
|
|
1.18 |
|
|
|
|
32,480,601 |
|
|
|
5.5 |
|
|
$ |
0.18 |
|
|
|
32,380,601 |
|
|
$ |
0.18 |
|
As of December 31, 2020, the
market price of the Company’s stock was $0.02 per share. At December 31, 2020 the aggregate intrinsic value of the options outstanding
was $0. Future unamortized compensation expense on the unvested outstanding options at December 31, 2020 is approximately $1,000.
Year Ending December
31, 2020
|
|
In January through December 31, 2020, the Company
issued options to purchase a total of 3,599,998 shares of common stock to employees, officers and members of the Board of Directors with
a fair value of $373,000 using the Black-Scholes Option Pricing model. The options are exercisable at $0.02 to $0.15 per share, vesting
over 3 to 12 months and expiring ten years from the date of grant.
During the year ended December 31, 2020, the Company
recognized compensation costs of $361,000 based on options that vested.
|
Year Ending December
31, 2019
|
|
In January 2019, the Company issued options to
purchase a total of 4,987,500 shares of common stock to employees, officers and members of the Board of Directors with a fair value of
$359,000 using the Black-Scholes Option Pricing model. The options are exercisable at $0.08 to $0.12 per share, vesting over 3 to 12 months
and expiring ten years from the date of grant.
During the year ended December 31, 2019, the Company
recognized compensation costs of $359,000 based on options that vested.
|
Black-Scholes Option
Pricing
The Company used the following
average assumptions in its calculation using the Black-Scholes Option Pricing model:
|
|
Years Ended |
|
|
|
2020 |
|
|
2019 |
|
Expected life (years) |
|
|
5.5 |
|
|
|
5.0 |
|
Risk free interest rate |
|
|
1.7% |
|
|
|
2.4% |
|
Volatility |
|
|
138% |
|
|
|
123% |
|
Expected dividend yield |
|
|
0% |
|
|
|
0% |
|
The assumptions used in the Black Scholes
models referred to above are based upon the following data: (1) the contractual life of the underlying non-employee options is the expected
life. The expected life of the employee option is estimated by considering the contractual term of the option, the vesting period of the
option and the employees’ expected exercise behavior. (2) The expected stock price volatility was based upon the Company’s
historical stock price over the expected term of the option. (3) The risk-free interest rate is based on published U.S. Treasury Department
interest rates for the expected terms of the underlying options. (4) The expected dividend yield was based on the fact that the Company
has not paid dividends to common shareholders in the past and does not expect to pay dividends to common shareholders in the future.
Warrants
The following table summarizes
certain information about the Company’s stock purchase warrants.
|
|
Warrants |
|
|
Weighted Avg. Exercise Price
|
|
Warrants outstanding, December 31, 2018 |
|
|
21,055,355 |
|
|
$ |
0.09 |
|
Warrants granted |
|
|
11,180,084 |
|
|
|
0.07 |
|
Warrants exercised |
|
|
(10,629,493 |
) |
|
|
0.05 |
|
Warrants cancelled |
|
|
(8,540,862 |
) |
|
|
0.07 |
|
Warrants outstanding, December 31, 2019 |
|
|
13,065,084 |
|
|
$ |
0.11 |
|
Warrants granted |
|
|
6,117,013 |
|
|
|
0.03 |
|
Warrants exercised |
|
|
(1,155,000 |
) |
|
|
0.05 |
|
Warrants cancelled |
|
|
(9,343,420 |
) |
|
|
0.07 |
|
Warrants outstanding, December 31, 2020 |
|
|
8,683,677 |
|
|
$ |
0.11 |
|
At December 31, 2020 the price
of the Company’s common stock was $0.02 per share and the aggregate intrinsic value of the warrants outstanding was $0. As of December
31, 2020, 8,650,344 warrants were fully vested and 33,333 warrants vest in January 2021.
|
|
Outstanding Warrants |
|
|
Exercisable Warrants |
|
Warrant
Exercise Price
Per Share |
|
Shares |
|
|
Life
(Years) |
|
|
Weighted Average Exercise Price |
|
|
Shares |
|
|
Weighted Average Exercise Price |
|
$ 0.05 - $ 0.24 |
|
|
6,613,677 |
|
|
|
0.8 |
|
|
$ |
0.04 |
|
|
|
6,580,344 |
|
|
$ |
0.04 |
|
$ 0.25 - $ 0.49 |
|
|
2,000,000 |
|
|
|
0.8 |
|
|
|
0.30 |
|
|
|
2,000,000 |
|
|
|
0.30 |
|
$ 0.50 - $ 1.00 |
|
|
70,000 |
|
|
|
3.3 |
|
|
|
0.80 |
|
|
|
70,000 |
|
|
|
0.80 |
|
|
|
|
8,683,677 |
|
|
|
0.8 |
|
|
$ |
0.11 |
|
|
|
8,650,344 |
|
|
$ |
0.11 |
|
Year Ending December 31, 2020
|
· |
In March through December 2020, pursuant to terms of convertible notes issued, the Company granted warrants to purchase 5,717,017 shares of common stock with an exercise price of $0.03 to $0.035 per share, vesting immediately upon grant and expiring one year from the date of grant. See Note 5 for further discussion. |
|
· |
In April through December 2020, pursuant to terms of a consulting agreement, the Company granted warrants to purchase 399,996 shares of common stock with an exercise price of $0.02 to $0.08 per share, vesting 1 to 3 months from the date of grant and expiring two years from the date of grant. Total fair value of these options at grant date was approximately $16,000 using the Black-Scholes Option Pricing model with the following assumptions: life of 2 years; risk free interest rate of 0.11% to 0.19%; volatility of 188% to 200%; and dividend yield of 0%. During the year ended December 31, 2020, the Company recognized compensation expense of $16,000 based on the fair value of the warrants that vested. |
Year Ending December 31, 2019
|
· |
In February through December 2019, pursuant to terms of convertible notes issued, the Company granted warrants to purchase 10,913,420 shares of common stock with an exercise price of $0.05 to $0.15 per share, vesting immediately upon grant and expiring one year from the date of grant. See Note 5 for further discussion. |
|
· |
In May through December 2019, pursuant to terms of a consulting agreement, the Company granted warrants to purchase 266,664 shares of common stock with an exercise price of $0.11 to $0.24 per share, vesting 1 to 3 months from the date of grant and expiring two years from the date of grant. Total fair value of these options at grant date was approximately $27,000 using the Black-Scholes Option Pricing model with the following assumptions: life of 2 years; risk free interest rate of 1.56% to 1.63%; volatility of 148% to 163%; and dividend yield of 0%. During the year ended December 31, 2019, the Company recognized compensation expense of $24,000 based on the fair value of the warrants that vested. |
|